Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200319 | 0.93 | CTSL (0.49) | MC4RCALCRLOPRM1OPRD1F2 | |
| SCHEMBL7200318 | 0.93 | CTSL (0.49) | MC4RCALCRLOPRM1OPRD1F2 | |
| SCHEMBL30366623 | 0.92 | ACE (0.48) | CALCRLACEOPRM1OPRD1ACE2 | |
| SCHEMBL31437160 | 0.89 | CTSL (0.56) | MC4RCALCRLOPRM1 | |
| SCHEMBL30910841 | 0.87 | CTSL (0.52) | MC4RACEF2 | |
| SCHEMBL29701316 | 0.86 | ACE (0.49) | ACEOPRM1OPRD1ACE2 | |
| SCHEMBL11308630 | 0.86 | ACE (0.45) | MC4RACEACE2 | |
| SCHEMBL30974084 | 0.86 | F2 (0.43) | MC4RBDKRB2OPRM1OPRD1F2 | |
| SCHEMBL31195334 | 0.85 | CALCRL (0.53) | CALCRLOPRM1OPRD1F2 | |
| SCHEMBL31437181 | 0.85 | MC4R (0.51) | MC4ROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | HALLSTAT CAPITAL, LLC | 2024-08-15 | — | — | US | disclosed |
| EP-4404912-A1 | ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE | Ferring B.V. (NL) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046336-A1 | ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE | FERRING B.V. (NL) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269226-A1 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | CNR2, CNR1, BAD | MC4R 490/4885CALCRL 346/4885BDKRB2 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.